Limits...
Chronic treatment with a carbon monoxide releasing molecule reverses dietary induced obesity in mice.

Hosick PA, AlAmodi AA, Hankins MW, Stec DE - Adipocyte (2015)

Bottom Line: Chronic treatment with CORM-A1 resulted in a 33% decrease from initial body weight over the 30 week treatment period while treatment with iCORM and saline were associated with 18 and 25% gain in initial body weight over the same time frame.Chronic treatment with CORM-A1 did not affect food intake or activity but resulted in a significant increase in metabolism.CORM-A1 treatment also resulted in lower fasting blood glucose, improvement in insulin sensitivity and decreased heptatic steatosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Physiology & Biophysics; Center for Excellence in Cardiovascular-Renal Research; University of Mississippi Medical Center; Jackson, MS USA; Department of Exercise Science and Physical Education; Montclair State University; Montclair, NJ USA.

ABSTRACT
Chronic, low level treatment with a carbon monoxide releasing molecule (CO-RM), CORM-A1, has been shown to prevent the development of obesity in response to a high fat diet. The objective of this study was to test the hypothesis that chronic, low level treatment with this CO-RM can reverse established obesity via a mechanism independent of food intake. Dietary induced obese mice were treated with CORM-A1, the inactive compound iCORM-A1, or saline every 48 hours for 30 weeks while maintained on a high fat (60%) diet. Chronic treatment with CORM-A1 resulted in a 33% decrease from initial body weight over the 30 week treatment period while treatment with iCORM and saline were associated with 18 and 25% gain in initial body weight over the same time frame. Chronic treatment with CORM-A1 did not affect food intake or activity but resulted in a significant increase in metabolism. CORM-A1 treatment also resulted in lower fasting blood glucose, improvement in insulin sensitivity and decreased heptatic steatosis. Chronic treatment with CO releasing molecules can reverse dietary induced obesity and normalize insulin resistance independent of changes in food intake or activity. These findings are likely though a mechanism which increases metabolism.

No MeSH data available.


Related in: MedlinePlus

(A) Representative images and quantification of hepatic steatosis as measured by Oil Red O staining of liver sections. (B) Liver to tibia length ratios in each group obtained at the end of the 30 week study. * = P < 0.05 as compared to other groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836479&req=5

f0006: (A) Representative images and quantification of hepatic steatosis as measured by Oil Red O staining of liver sections. (B) Liver to tibia length ratios in each group obtained at the end of the 30 week study. * = P < 0.05 as compared to other groups.

Mentions: Increased fat storage in the liver is a significant complication of dietary-induced obesity. We determined the level of hepatic steatosis in mice from each treatment group by Oil Red O staining of liver sections obtained from samples at the end of the study. Oil Red O staining averaged around 53% in all 3 control groups but only averaged 25 ± 6% in mice treated with CORM-A1 (Fig. 6A). CORM-A1 treatment also had a significant effect to reduce overall liver weights in dietary-induced obese mice. CORM-A1 treatment decreased liver to tibia length ratios by 50% as compared to all non-treated mice (Fig. 6B).Figure 6.


Chronic treatment with a carbon monoxide releasing molecule reverses dietary induced obesity in mice.

Hosick PA, AlAmodi AA, Hankins MW, Stec DE - Adipocyte (2015)

(A) Representative images and quantification of hepatic steatosis as measured by Oil Red O staining of liver sections. (B) Liver to tibia length ratios in each group obtained at the end of the 30 week study. * = P < 0.05 as compared to other groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836479&req=5

f0006: (A) Representative images and quantification of hepatic steatosis as measured by Oil Red O staining of liver sections. (B) Liver to tibia length ratios in each group obtained at the end of the 30 week study. * = P < 0.05 as compared to other groups.
Mentions: Increased fat storage in the liver is a significant complication of dietary-induced obesity. We determined the level of hepatic steatosis in mice from each treatment group by Oil Red O staining of liver sections obtained from samples at the end of the study. Oil Red O staining averaged around 53% in all 3 control groups but only averaged 25 ± 6% in mice treated with CORM-A1 (Fig. 6A). CORM-A1 treatment also had a significant effect to reduce overall liver weights in dietary-induced obese mice. CORM-A1 treatment decreased liver to tibia length ratios by 50% as compared to all non-treated mice (Fig. 6B).Figure 6.

Bottom Line: Chronic treatment with CORM-A1 resulted in a 33% decrease from initial body weight over the 30 week treatment period while treatment with iCORM and saline were associated with 18 and 25% gain in initial body weight over the same time frame.Chronic treatment with CORM-A1 did not affect food intake or activity but resulted in a significant increase in metabolism.CORM-A1 treatment also resulted in lower fasting blood glucose, improvement in insulin sensitivity and decreased heptatic steatosis.

View Article: PubMed Central - PubMed

Affiliation: Department of Physiology & Biophysics; Center for Excellence in Cardiovascular-Renal Research; University of Mississippi Medical Center; Jackson, MS USA; Department of Exercise Science and Physical Education; Montclair State University; Montclair, NJ USA.

ABSTRACT
Chronic, low level treatment with a carbon monoxide releasing molecule (CO-RM), CORM-A1, has been shown to prevent the development of obesity in response to a high fat diet. The objective of this study was to test the hypothesis that chronic, low level treatment with this CO-RM can reverse established obesity via a mechanism independent of food intake. Dietary induced obese mice were treated with CORM-A1, the inactive compound iCORM-A1, or saline every 48 hours for 30 weeks while maintained on a high fat (60%) diet. Chronic treatment with CORM-A1 resulted in a 33% decrease from initial body weight over the 30 week treatment period while treatment with iCORM and saline were associated with 18 and 25% gain in initial body weight over the same time frame. Chronic treatment with CORM-A1 did not affect food intake or activity but resulted in a significant increase in metabolism. CORM-A1 treatment also resulted in lower fasting blood glucose, improvement in insulin sensitivity and decreased heptatic steatosis. Chronic treatment with CO releasing molecules can reverse dietary induced obesity and normalize insulin resistance independent of changes in food intake or activity. These findings are likely though a mechanism which increases metabolism.

No MeSH data available.


Related in: MedlinePlus